Evidence map›Paper›PMID 41787903›Full record

ArticleArchives of craniofacial surgery2026

Role of hyperbaric oxygen therapy in oral submucous fibrosis: a randomized comparative study from India.

Rukmini Sah, Vibha Singh, Uma Shanker Pal, Shadab Mohammad, Vijay Kumar, Veerendra Verma, Amiya Agrawal, Sandhya Pandey, Ranjana Singh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of craniofacial surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rukmini SahDepartment of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, India.
Vibha SinghDepartment of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, India.
Uma Shanker PalDepartment of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, India.
Shadab MohammadDepartment of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, India.
Vijay KumarDepartment of Plastic and Reconstructive Surgery, King George's Medical University, Lucknow, India.
Veerendra VermaDepartment of Otorhinolaryngology (ENT), King George's Medical University, Lucknow, India.
Amiya AgrawalDepartment of Oral and Maxillofacial Surgery, King George's Medical University, Lucknow, India.
Sandhya PandeyDepartment of Plastic and Reconstructive Surgery, King George's Medical University, Lucknow, India.
Ranjana SinghDepartment of Biochemistry, King George's Medical University, Lucknow, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo assess the effectiveness of hyperbaric oxygen therapy (HBOT) as an adjunct to standard treatment in early-stage oral submucous fibrosis (OSMF), focusing on mouth opening, burning sensation, pain, and systemic inflammation.

methodsA randomized comparative study was conducted on early-stage OSMF patients divided into two groups. Group 1 received HBOT along with intralesional triamcinolone, hyaluronidase, and oral antioxidants. Group 2 received only the standard intralesional therapy with antioxidants. Clinical parameters-interincisal distance, burning sensation, and pain-were recorded at baseline, first, and second follow-up. Serum C-reactive protein (CRP) levels were measured pre- and post-treatment. Statistical analysis included unpaired t-tests and chi-square tests.

resultsBoth groups improved clinically, but Group 1 showed significantly greater reductions in burning sensation (p= 0.020), pain, and CRP levels (p= 0.033). Although intergroup differences in mouth opening were not statistically significant, Group 1 showed greater improvement over time. Fibrotic band distribution remained unchanged in both groups. No complications were reported with HBOT.

conclusionHBOT provides enhanced symptomatic relief and anti-inflammatory effects in early-stage OSMF when used alongside conventional therapy. While it may not reverse fibrosis, its safety and noninvasive nature support its role in multimodal OSMF management.

Indexed as

HyaluronidaseHyperbaric oxygenationOral submucous fibrosisTriamcinolone

Identifiers

PMID41787903
PMCPMC12968648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.